NEW YORK (GenomeWeb News) – BGI and H3 Biomedicine today announced they will sequence and publish data from next-generation sequencing-based research on pre-clinical cancer models.

In the first study to be performed under the terms of the partnership, BGI will sequence 250 cancer cell lines using next-generation whole-exome sequencing. It and H3 Biomedicine will jointly analyze the data and then deliver a highly curated set of "genetically profiled, pre-clinical model information that will help to accelerate drug discovery and development efforts."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

In Genome Biology this week: miRNAs linked to diffuse large B-cell lymphoma outcomes, database of bird genomes, and more.